351 related articles for article (PubMed ID: 11772120)
1. Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson's disease.
Ross GW; Petrovitch H
Drugs Aging; 2001; 18(11):797-806. PubMed ID: 11772120
[TBL] [Abstract][Full Text] [Related]
2. Novel neuroprotection by caffeine and adenosine A(2A) receptor antagonists in animal models of Parkinson's disease.
Kalda A; Yu L; Oztas E; Chen JF
J Neurol Sci; 2006 Oct; 248(1-2):9-15. PubMed ID: 16806272
[TBL] [Abstract][Full Text] [Related]
3. Effects of caffeine in Parkinson's disease: from neuroprotection to the management of motor and non-motor symptoms.
Prediger RD
J Alzheimers Dis; 2010; 20 Suppl 1():S205-20. PubMed ID: 20182024
[TBL] [Abstract][Full Text] [Related]
4. Effect of caffeine on the expression of cytochrome P450 1A2, adenosine A2A receptor and dopamine transporter in control and 1-methyl 4-phenyl 1, 2, 3, 6-tetrahydropyridine treated mouse striatum.
Singh S; Singh K; Gupta SP; Patel DK; Singh VK; Singh RK; Singh MP
Brain Res; 2009 Aug; 1283():115-26. PubMed ID: 19520064
[TBL] [Abstract][Full Text] [Related]
5. Caffeinated clues and the promise of adenosine A(2A) antagonists in PD.
Schwarzschild MA; Chen JF; Ascherio A
Neurology; 2002 Apr; 58(8):1154-60. PubMed ID: 11971080
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease.
Chen JF; Xu K; Petzer JP; Staal R; Xu YH; Beilstein M; Sonsalla PK; Castagnoli K; Castagnoli N; Schwarzschild MA
J Neurosci; 2001 May; 21(10):RC143. PubMed ID: 11319241
[TBL] [Abstract][Full Text] [Related]
7. Systemically administered neuregulin-1β1 rescues nigral dopaminergic neurons via the ErbB4 receptor tyrosine kinase in MPTP mouse models of Parkinson's disease.
Depboylu C; Rösler TW; de Andrade A; Oertel WH; Höglinger GU
J Neurochem; 2015 May; 133(4):590-7. PubMed ID: 25581060
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotective effects of caffeine in MPTP model of Parkinson's disease: A (13)C NMR study.
Bagga P; Chugani AN; Patel AB
Neurochem Int; 2016 Jan; 92():25-34. PubMed ID: 26626997
[TBL] [Abstract][Full Text] [Related]
9. Neuroprotection by caffeine in the MPTP model of parkinson's disease and its dependence on adenosine A2A receptors.
Xu K; Di Luca DG; Orrú M; Xu Y; Chen JF; Schwarzschild MA
Neuroscience; 2016 May; 322():129-37. PubMed ID: 26905951
[TBL] [Abstract][Full Text] [Related]
10. Nicotine- and caffeine-mediated changes in gene expression patterns of MPTP-lesioned mouse striatum: Implications in neuroprotection mechanism.
Singh K; Singh S; Singhal NK; Sharma A; Parmar D; Singh MP
Chem Biol Interact; 2010 Apr; 185(2):81-93. PubMed ID: 20230807
[TBL] [Abstract][Full Text] [Related]
11. [Caffeine as a preventive drug for Parkinson's disease: epidemiologic evidence and experimental support].
Góngora-Alfaro JL
Rev Neurol; 2010 Feb 16-28; 50(4):221-9. PubMed ID: 20198594
[TBL] [Abstract][Full Text] [Related]
12. KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse.
Pierri M; Vaudano E; Sager T; Englund U
Neuropharmacology; 2005 Mar; 48(4):517-24. PubMed ID: 15755479
[TBL] [Abstract][Full Text] [Related]
13. The expression of CYP2D22, an ortholog of human CYP2D6, in mouse striatum and its modulation in 1-methyl 4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease phenotype and nicotine-mediated neuroprotection.
Singh S; Singh K; Patel DK; Singh C; Nath C; Singh VK; Singh RK; Singh MP
Rejuvenation Res; 2009 Jun; 12(3):185-97. PubMed ID: 19594327
[TBL] [Abstract][Full Text] [Related]
14. Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
Xu K; Xu Y; Brown-Jermyn D; Chen JF; Ascherio A; Dluzen DE; Schwarzschild MA
J Neurosci; 2006 Jan; 26(2):535-41. PubMed ID: 16407551
[TBL] [Abstract][Full Text] [Related]
15. Neuroprotective effect of silymarin in a MPTP mouse model of Parkinson's disease.
Pérez-H J; Carrillo-S C; García E; Ruiz-Mar G; Pérez-Tamayo R; Chavarría A
Toxicology; 2014 May; 319():38-43. PubMed ID: 24607817
[TBL] [Abstract][Full Text] [Related]
16. Electroacupuncture Promotes Recovery of Motor Function and Reduces Dopaminergic Neuron Degeneration in Rodent Models of Parkinson's Disease.
Lin JG; Chen CJ; Yang HB; Chen YH; Hung SY
Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28837077
[TBL] [Abstract][Full Text] [Related]
17. Caffeine neuroprotective effects on 6-OHDA-lesioned rats are mediated by several factors, including pro-inflammatory cytokines and histone deacetylase inhibitions.
Machado-Filho JA; Correia AO; Montenegro AB; Nobre ME; Cerqueira GS; Neves KR; Naffah-Mazzacoratti Mda G; Cavalheiro EA; de Castro Brito GA; de Barros Viana GS
Behav Brain Res; 2014 May; 264():116-25. PubMed ID: 24525422
[TBL] [Abstract][Full Text] [Related]
18. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
During MJ; Kaplitt MG; Stern MB; Eidelberg D
Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
[TBL] [Abstract][Full Text] [Related]
19. Nicotine and caffeine-mediated modulation in the expression of toxicant responsive genes and vesicular monoamine transporter-2 in 1-methyl 4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease phenotype in mouse.
Singh S; Singh K; Patel S; Patel DK; Singh C; Nath C; Singh MP
Brain Res; 2008 May; 1207():193-206. PubMed ID: 18374908
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease.
Schwarzschild MA; Xu K; Oztas E; Petzer JP; Castagnoli K; Castagnoli N; Chen JF
Neurology; 2003 Dec; 61(11 Suppl 6):S55-61. PubMed ID: 14663012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
